Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

[1]  H. Drexler,et al.  Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. , 1998, Leukemia research.

[2]  F. Liu,et al.  Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. Garcia,et al.  Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase‐3β , 2002 .

[4]  S. Clarke,et al.  Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.

[5]  Toshikazu Nakamura,et al.  Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. , 2004, Experimental hematology.

[6]  Toshikazu Nakamura,et al.  Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1α, and stem cell factor , 2004 .

[7]  I. S. Dunn,et al.  Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.

[8]  J. Blay,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors , 2006, Clinical Cancer Research.

[9]  A. Birukova,et al.  Magnitude-dependent effects of cyclic stretch on HGF- and VEGF-induced pulmonary endothelial remodeling and barrier regulation. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[10]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[11]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[12]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.

[13]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[14]  I. Wilhelm,et al.  Transmigration of Melanoma Cells through the Blood-Brain Barrier: Role of Endothelial Tight Junctions and Melanoma-Released Serine Proteases , 2011, PloS one.

[15]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[16]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[17]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[18]  A. Giobbie-Hurder,et al.  The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition , 2012, Clinical Cancer Research.

[19]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[20]  M. Donia,et al.  BRAF inhibition improves tumor recognition by the immune system , 2012, Oncoimmunology.

[21]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[22]  France Mentré,et al.  Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[24]  J. Sosman,et al.  Impact of MET expression on outcome in BRAFV600E/K advanced melanoma , 2013, Histopathology.

[25]  F. Goldwasser,et al.  An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  G. Freeman,et al.  Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade , 2014, Cancer Immunology Research.

[27]  Y. Shimada,et al.  Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer , 2014, British Journal of Cancer.

[28]  M. Mihm,et al.  Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors , 2013, Modern Pathology.

[29]  A. Ribas,et al.  The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics , 2014, Journal of clinical pharmacology.

[30]  H. Yatsuhashi,et al.  Hepatocyte growth factor enhances the barrier function in primary cultures of rat brain microvascular endothelial cells. , 2014, Microvascular research.

[31]  J. Utikal,et al.  Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  F. Goldwasser,et al.  Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma , 2016, Targeted Oncology.

[33]  C. Funck-Brentano,et al.  Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  G. Linette,et al.  Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. , 2015 .

[35]  T. Graeber,et al.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.

[36]  R. Dummer,et al.  A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma , 2015, Pharmacology research & perspectives.

[37]  C. Lebbé,et al.  Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  L. Chin,et al.  Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma , 2016, Oncoimmunology.